INDIA MARKET LENS

NATCO Pharma Limited (NATCOPHARM): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for NATCO Pharma Limited, explained in plain English.

  • NATCO Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • NATCOPHARM closed at ₹814.30 on 20 November 2026.
  • Over the past year the shares are down 6.3%, trading between ₹773.60 and ₹1,226.80.
  • Reported fundamentals show return on equity of 9.01%, a net margin of 26.79%, debt to equity of 10.58.
  • Our Pulse grade checklist scores it D (41/100) across momentum, growth, profitability and safety on fixed thresholds.
  • Annualised volatility over the past year is 35.32% with a maximum drawdown of -35.19% and a beta of 0.8 against NIFTY 50.
  • Recent coverage: Stock Market Today: Sensex Off Highs, Up 300 Points, Nifty 50 Near 25,200; Natco Pharma Zooms 7%, Kaynes Tanks 10%
  • Recent coverage: Natco Pharma Q2 Results: Net Profit Falls 61% To Rs 203 Crore, Revenue Declines 29%; Stock Tumbles 3%

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 20 Nov 2026. Closed — weekend.

NATCO Pharma Limited (NATCOPHARM)

₹814.3

▼ 7.65 (-0.93%)

Price & volume

NATCOPHARM price chart, 1Y range. 252 points from 2025-11-24 to 2026-11-20. Opens at 841.25, closes at 814.3, ranging between 781.6 and 1,206.8009001,0001,1001,200Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Neutral momentum · 3/5
✓ Above 50-day avg✕ Above 200-day avgRSI 54.3 · healthyMACD positiveBollinger %B 71ADX 23.5 · weak trend

1M

+1.68%

3M

-7.20%

6M

-29.58%

1Y

-6.33%

Where it sits in its 52-week range

8%
₹781.6₹1,206

Below 52-week high

32.5%

4.2% above the low

Momentum read

Neutral

3/5 checks passed

52-wk high

₹1,206

52-wk low

₹781.6

Market cap

₹15,974 Cr

P/E (trailing)

17.7

Dividend yield

—

ROE

9.01%

Profit margin

26.79%

Revenue growth

-29%

Price / Book

1.49

Debt / Equity

10.58

EPS (TTM)

45.89

Book value

₹545.11

Beta

0.81

Pulse grade: D, 41 out of 100

Momentum

C
  • ✓Trading above 50-day average
  • ✕Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

F
  • ✕Revenue growth above 12%
  • ✕Revenue growing above 5%
  • ✕Quarterly profits trending up

Profitability

D
  • ✕Return on equity above 18%
  • ✕Return on equity above 12%
  • ✓Profit margin above 12%

Safety

A
  • ✓Debt below 50
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹967 crore · net profit ₹203 crore · margin 21.0%

1,3630Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,884.9-0.79%-5.81%
DRREDDY1,390.2-0.76%-0.76%
CIPLA1,415-0.25%-7.59%
DIVISLAB11,180.5+0.02%-3.33%
APOLLOHOSP9,200+5.29%0.00%
LUPIN2,014+0.76%-19.91%

NATCOPHARM headlines

No NATCOPHARM stories right now.

NATCOPHARM filings & announcements

Reading the exchange…

NATCOPHARM, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

35.32%

Sharpe ratio

-0.09

Sortino ratio

-0.13

Max drawdown

-35.19%

Daily VaR (95%)

-2.93%

CAGR (1Y)

-3.22%

Return skew

-0.36

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.